[Medical and commercial aspects of human interferon].
High expectations placed in the importance of the interferons for viral and cancer therapy caused the pharmaceutical industry at an early stage to accelerate interferon research with considerable financial effort. As a matter of fact, the interferons as yet exhibited effects mainly with indications which represent an outstanding ethical provocation indeed, but do not allow to expect a relevant market due to low case numbers. Of the approx. 70 companies temporarily involved in interferon projects only some 10 participate in this research with the necessary commitment. However, their market expectancies also are met only if the indications for interferons can be extended by further study programmes and the therapeutic use does not fail due to bureaucratic obstacles.
J F
JF
von Eichborn
D000970:Antineoplastic Agents; D000998:Antiviral Agents; D003365:Costs and Cost Analysis; D004345:Drug Industry; D006801:Humans; D007370:Interferon Type I / Q000096:biosynthesis; D007371:Interferon-gamma / Q000096:biosynthesis; D007372:Interferons / Q000096:biosynthesis / Q000627:therapeutic use*; D011994:Recombinant Proteins
D000970:Antineoplastic Agents; D000998:Antiviral Agents; D007370:Interferon Type I; D011994:Recombinant Proteins; D007371:Interferon-gamma; D007372:Interferons
Medizinische und kommerzielle Aspekte der menschlichen Interferone.